Filter By Industry
Filter By Tag

Newsroom

ReStem Biotech Press releases

1 - 10 of 10 Press Releases

Re-Stem Biotech Awarded 2020 Ernst & Young Fudan "China's Most Promising Company" Award
Oct 14, 2020
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers was recently presented a 2020 "China's Most Promising Company" award.

Re-Stem-Funded Study Targeting Mitochondrial Dysfunction in Aging and Age-Related Diseases Published in Science Advances Journal
Aug 09, 2020
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers recently funded in part a study titled "Solid-phase inclusion as a...

Re-Stem Biotech Provides Banking of Immune Cells for Medical Staff in Hubei
Feb 11, 2020
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, recently provided the...

Re-Stem Biotech Receives GMP Certification of its Upgraded Cleanrooms in Suzhou
Dec 11, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced that it..

Re-Stem Biotech Signs Cooperation Agreement with International Health Industry Park in Wuhan, China
Nov 01, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced that...

Re-Stem Biotech Research Collaboration Featured on Johns Hopkins Technology Ventures' Website
Sep 19, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, has recently been...

Re-Stem Biotech Expands Cell Manufacturing and Banking Facilities to Kunming, China
Aug 22, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced the...

Re-Stem Biotech to hold Grand Opening of New Location and Expansion of its Corporate Office and R&D Facility
May 15, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, spinal cord injury and cancer, today announced a Grand Opening..

Re-Stem Biotech Sponsors Guangdong Private Entrepreneurs Golf Association Invitational Tournament
Apr 02, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, spinal cord injury and cancer, sponsored the Guangdong Private..

Re-Stem Biotech Announces Publication in "Nature Neuroscience" of Scientific Study Related to Company's Development of Spinal Cord Injury Treatment
Feb 25, 2019
Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products, including osteoarthritis, spinal cord injury and various cancers today announced that Wutian Wu, PhD, Clinical...


ReStem Biotech RSS Feed